Back to the main directory
EarningsReview / Equity
- Gjensidige - Poor delivery at a time when improvement is needed by Danske Bank Equity Research
- Streamwide - En croissance, une nouvelle fois by MidCap Partners
- Streamwide - Growing, once again by MidCap Partners
- INVEST SECURITIES - AFFLUENT MEDICAL : Un accord très structurant avec EDWARDS ! - ACHAT, OC 4,4€ vs 3,3€ by Invest Securities
- Record - Transitional year ahead by Edison Investment Research
- Non material data changes by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Who’s got the (pricing) power? by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Happy Anniversary; More Upside Potential Ahead by BNP Paribas Exane
- AFRY - Recovering margins by Danske Bank Equity Research
- Eastroc Beverage (605499 CH) by HSBC
- Fundraising and activity picking up by BNP Paribas Exane
- Aker Horizons - Positive trend but much remains to be proven by Danske Bank Equity Research
- Sweco - Executing the game plan by Danske Bank Equity Research
- KlaraBo - Missing out on the rate decline by Danske Bank Equity Research
- Peab - A mixed bag, but the positives outweigh by Danske Bank Equity Research
- Enento Group - Inching back towards growth by Danske Bank Equity Research
- NCC - Asphalt laid the foundation for the earnings beat by Danske Bank Equity Research
- Castellum - Running a tight ship by Danske Bank Equity Research
- Kitron (Buy, TP: NOK42.00) - Recovery still in the early innings by DnB Markets
- Ericsson (Buy, TP: SEK83.00) - Earnings trough in the rear view by DnB Markets
- Sagax (Sell, TP: SEK240.00) - PFPMps adj. growth to trough in Q3e by DnB Markets
- Ncc (Buy, TP: SEK175.00) - Q2 beat, divestments next by DnB Markets
- Nel (Sell, TP: NOK3.50) - Valuation still appears excessive by DnB Markets
- Catana Group SA - Une vision à long terme by MidCap Partners
- Catana Group SA - A long term vision by MidCap Partners
- INVEST SECURITIES - MEDESIS : Trésorerie étendue à octobre 2024, verdict fin T3 24 - NEUTRE, OC 3,3€ by Invest Securities
- Non material data changes by BNP Paribas Exane
- Solid Q2 but destocking continues to be a drag by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Better quality, higher price by BNP Paribas Exane
- Biotage - Strong organic growth and positive outlook by Danske Bank Equity Research
- Updating estimates ahead of 2Q reporting by BNP Paribas Exane
- Q1 sales: through the worst of the weather by BNP Paribas Exane
- 东鹏饮料（605499 CH） by HSBC
- 2Q24 production - Improving, but less than expected by BNP Paribas Exane
- Top-line slowdown but B2B outlook improving by BNP Paribas Exane
- Feng Tay Enterprises (9910 TT) by HSBC
- Trimming estimates ahead of 1H24 results by BNP Paribas Exane
- WEBUILD: coverage dropped by BNP Paribas Exane
- 2Q24 Preview: Thoughts Ahead of the Print by BNP Paribas Exane
- Bergman & Beving - Strengthening the foundation for continued success by Danske Bank Equity Research
- WithSecure - Moving in the right direction, but in slow motion by Danske Bank Equity Research
- Sensitive piloting by BNP Paribas Exane
- Veidekke (Buy, TP: NOK135.00) - M&A and market boost for EPS by DnB Markets
- Fortnox (Buy, TP: SEK84.00) - Moving to easier comparables by DnB Markets
- OX2 (Hold, TP: SEK60.00) - Limited earnings in Q2e by DnB Markets
- NTG (Buy, TP: DKK350.00) - by DnB Markets
- Swedbank (Buy, TP: SEK245.00) - ROE & NII continuing to normalise by DnB Markets